long unique region, a deletion in the repeat region, a 1460 bp deletion in the gl coding region and a 1414 bp deletion in the gpX coding region. The S-PRV-155 can be used in live or inactivated form in vaccines for immunizing animals, especially pigs, against PRV disease. In an example, S-PRV-155 was derived from S-PRV-002 through the construction of three intermediate viruses: (1) S-PRV-070, in which the Xba| restriction endonuclease sites were converted to EcoRI sites using a synthetic oligonucleotide; (2) S-PRV-146, in which the gl deletion was introduced along with the fl-galactosidase (b-GAL, EC 3.2.1.23) reporter gene using vector 416-09.2H and virus S-PRV-070 by homologous recombination; and (3) S-PRV-154, which was generated using the vector 436-86.32K and S-PRV-153 by homologous recombination to delete the gpX gene. S-PRV-155 resulted from the removal of the b-GAL reporter gene from S-PRV-154 by digestion with Xbal.

029-93

Vaccine comprises recombinant attenuated pox virus; recombinant modified vaccinia virus with attenuated virulence; used for vaccinating against viral infections such as rabies virus, hepatitis B virus, HIV virus, etc.; DNA sequence Virogenetics World 9215 672; 17 September 1992

A modified recombinant virus (I) has its virus-encoded genetic functions associated with virulence inactivated so that the virus has attenuated virulence. Also claimed are: i. a vaccine for inducing an immunological response in a host animal comprising a carrier and (I); ii. a method for expressing a gene product in a cell cultured in vitro comprising introducing (I) into a cell; and iii. a modified vector for expressing a gene product in a cell cultured in vitro; and iv. a modified vector for expressing a gene product in a host, the vector being modified so that it has attenuated virulence in the host. Genetic functions may be inactivated by deletion or insertional inactivation of an open reading frame encoding a virulence factor. (I) may include the recombinant vaccinia virus vP410, vP553, vP879, vP999, vP618, vP723, vP804, vP866, vP796, vP938, vP953, vP977, vP954 or NYVAC, etc. The safer vaccine may be used to prevent infection by a pox virus, particularly a vaccinia virus, or an avipox virus, such as fowlpox virus and canarypox virus.

030-93

Recombinant FIV virus gpl60, 0.4, 0.6, 1.2 envelope protein from Escherichia coli; expression in eukaryote cell culture; monoclonal antibody production and recombinant vaccine production Cambridge Biotech World 9215 684; 17 September 1992

The following arc claimed: (a) recombinant FIV ,irus (l~lV) gpl60 envelope protein obtained from cells infected with FIV: Ib) recombinant FIV 0.4 envelope protein obtained from Escherichia coil MZ-I infected with FIV; (c) recombinant FIV 1.2 envelope protein obtained from FIV Bangstrom strain (BS): (d) recombinant F1V gag 0.6 fragment obtained from FIV BS (e) a plasmid containing a DNA sequence encoding FIV 0.4 envelope protein, FIV gp160-containing protein, FIV envelope protein of FIV BS, FIV 1.2 envelope protein or FIV gag 0.6 fragment; (f) a eukaryotic cell transformed with a plasmid as in (e); (g) a monoclonal antibody against the FIV envelope protein as in (a) (c) or FIV gag 0.6 fragment as in (d); and (h) preparation of a composition used to induce FIV antibodies production in a cat, by admixing a protein containing the protein sequence of FIV gag 0.6 fragment with a carrier. Genomic DNA is extracted from FIV-infected cat peripheral blood leukocytes, and FIV sequence data is used to create primers for the polymerase chain reaction to amplify the FIV region, which is cloned and expressed to obtain FIV protein fragments.

031 93

Attenuated bacterium expressing heteroiogous protein e.g. Bordetella pertussis P69 protein or Clostridium tetani tetanus toxin fragment-C, expressed from the nirB promoter and induced anaerobic conditions, for use as live recombinant vaccine Wellcome World 9215 689; 17 September 1992

A new attenuated bacterium is capable of expressing a heterologous protein under the control of a promoter whose activity is induced by anaerobic conditions. The attenuated bacterium preferably has a non-reverting mutation in coding or regulatory DNA governing expression of a protein produced in response to environmental stress, e.g. an aroA, aroC, aroA aroD or aroA aroE mutant. The promoter is preferably a nirB promoter. The heterologous protein may be an antigen from a virus, bacterium, fungus, yeast or parasite, e.g. Bordetella pertussis P69 protein or Clostridium tetani tetanus toxin fragment-C. The new strain is produced by transforming an attenuated bacterium with a vector containing the promoter operably linked to the antigen sequence, and may be used as a live recombinant vaccine. In an example, plasmid pTETnirl 5 was constructed by replacing a region in plasmid pTETtac115, containing the lac| gene and tac promoter, with the nirB promoter. Salmonella typhimurium LB5010 was transformed with pTETnirl5, and colonies expressing tetanus toxin fragment-C were identified.

032 93

488 Vaccine, Vol. 11, Issue 4, 1993